Cancer histopathology

Generally, histopathology and cytopathology have been the fundamental apparatuses used in the conclusion of malignancy. These methods have developed from a time of finding dependent on haematoxylin and eosin (H&E) recoloured slides (Figure 1) to the present normal assessment of tumors by immunocytochemistry (IHC) to affirm tumour histogenesis and subtype. In bosom malignancy, this implies the routine IHC assessment of hormone receptors (estrogen (Figure 2) and progesterone receptors) just as assessment of HER2 articulation (Figure 3) and Ki67 (a marker of tumor expansion). These elements emphatically impact anticipation and the choice of hostile to malignant growth medications. Sub-atomic histopathology utilizing in-situ hybridization (ISH) systems likewise gives extra data affecting guess and treatment in bosom malignant growth (Figure 4) and different diseases. All the more as of late, quality profiling innovation (Figure 5) has been utilized to characterize subgroups of bosom disease patients. For instance, it has distinguished the Luminal-A bosom malignant growth subtype for whom adjuvant chemotherapy is probably not going to be of advantage. These quality profiling procedures are probably going to be utilized in the administration of different tumors over coming years

    Related Conference of Cancer histopathology

    December 11-12, 2025

    6th International Conference on Breast Pathology and Cancer Diagnosis

    Amsterdam, Netherlands
    March 26-27, 2026

    24th Annual Pathology Congress

    Dubai, UAE
    June 22-23, 2026

    24th European Pathology Congress

    Paris, France

    Cancer histopathology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in